Glycogen synthase kinase-3 inhibitors

Details Glycogen synthase kinase-3 inhibitors Glycogen synthase kinase-3 inhibitors

2008-05-27

2008-05-27

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S255000

Reexamination Certificate

active

07378432

ABSTRACT:
Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.

REFERENCES:
patent: 5749925 (1998-05-01), Bocker et al.
patent: 6057117 (2000-05-01), Harrison et al.
patent: 6153618 (2000-11-01), Schultz et al.
patent: 6441140 (2002-08-01), Comb et al.
patent: 6495376 (2002-12-01), Lu et al.
patent: 6780625 (2004-08-01), Eldar-Finkelman
patent: 2002/0147146 (2002-10-01), Eldar-Finkelman
patent: 2004/0162234 (2004-08-01), Eldar-Finkelman
patent: WO 95/01376 (1995-01-01), None
patent: WO 97/33601 (1997-09-01), None
patent: WO 97/41854 (1997-11-01), None
patent: WO 98/16528 (1998-04-01), None
patent: WO 00/45237 (2000-03-01), None
patent: WO 00/59206 (2000-05-01), None
patent: WO 00/74663 (2000-12-01), None
patent: WO 01/49709 (2001-07-01), None
patent: WO 02/24941 (2002-03-01), None
patent: WO 2004/052404 (2004-06-01), None
patent: WO 2005/000192 (2005-06-01), None
Donella-Deana et al. “Dephosphorylation of Phosphopeptides by Colcineurin (Protein Phosphatase 2B)”, European Journal of Biochemistry, 219(1-2): 109-117, 1994. Tab.1, 2.
Fu et al. “Design and Synthesis of A Pyrodone-Based Phosphtyrosine Mimetic”, Bioorganic and Medicinal Chemistry Letters, 8(19): 2813-2816, 1998.
Gao et al. “Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2,4-(2-Malonyl)Phenylalanine as A Potent Phosphotyrosyl Mimetic”, Journal of Medicinal Chemistry, 43(5): 911-920, 2000.
Gething et al. “Cell-Surface Expression of Influenza Haemagglutinin From A Cloned DNA Copy of the RNA Gene”, Nature, 293(5834): 620-625, 1981.
Groves et al. “Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics”, Biochemistry, 37(51): 17773-17783, 1998.
Hallstrom et al. “Regulation of Transcription Factor Pdr1p Function by An Hsp70 Protein inSaccharomyces Cerevisiae”, Molecular and Cellular Biology, 18(3): 1147-1155, 1998.
Hanger et al. “Glycogen Synthase Kinase-3 Induces Alzheimers Disease-Like Phosphorylation of Tau: Generation of Paired Helical Filament Epitopes and Neuronal Localisatoin of the Kinase”, Neuroscience Letters, 147: 58-62, 1992.
Hawinger “Cellular Import of Functional Peptides to Block Intracellular Signaling”, Current Opinion in Immunology, 9(2): 189-194, 1997.
He et al. “Glycogen Synthase Kinase-3 and Dorsoventral Patterning inXenopusEmbryos”, Nature, 374(6523): 617-622, 1995.
Higashimoto et al. “Human P53 Is Phosphorylated on Serines 6 and 9 in Response to DNA Damage-Inducing Agents”, The Journal of Biological Chemistry, 275(30): 23199-23203, 2000.
Klein et al. “A Molecular Mechanism for the Effect of Lithium on Development”, Proc. Natl. Acad. Sci. USA, 93: 8455-8459, 1996.
Kole et al. “Protein-Tyrosine Phosphatase Inhibition by A Peptide Containing the Phosphotyrosyl Mimetic, L-O-Malonyltyrosine”, Biochemical and Biophysical Research Communications, 209(3): 817-822, 1995.
Kole et al. “Specific Inhibition of Insulin Receptor Dephosphorylation by A Synthetic Dodecapeptide Containing Sulfotyrosyl Residues as Phosphotyrosyl Mimetic”, Indian Journal of Biochemistry & Biophysics, 34(1-2): 50-55, 1997.
Latimer et al. “Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosphorylation of Transfected Tau”, FEBS Letters, 365: 42-46, 1995.
Lucas et al. “Decreased Nuclear Beta-Catenin, Tahyperphosphorylation and Neurodegeneration in GSK-3Beta Conditional Transgenic Mice”, The EMBO Journal, 20:27-39, 2001.
Lovestone et al. “Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells”, Current Biology, 4: 1077-1086, 1995.
Mandelkow et al. “Tau as A Marker for Alzheimer's Disease”, Trends in Biochemical Sciences, 18(12): 480-483, 1983.
Mandelkow et al. “Glycogen Synthase Kinase-3 and the Alzheimer-Like State of Micortubule-Associated Protein Tau”, FEBS Letters, 314: 315-321,1992.
Manji et al. “Lithium at 50: Have the Neuroprotective Effects of This Unique Cation Been Overlooked?”, Biological Psychiatry, 46(7): 929-940, 1999.
McKinsey et al. “Phosphorylation of the PEST Domain of IkappaBbeta Regulates the Function of NF-KappaB/IkappaBbeta Complexes”, The Journal of Biological Chemistry, 272(36): 22377-22380, 1997.
Merrifield et al. “Solid Phase Peptide Synthesis. I. The Synthesis of A Tetrapeptide”, Journal of the American Chemical Society, 85: 2149-2154, 1963.
Mikol et al. “The Crystal Structures of the SH2 Domain of P561ck Complexed With Two Phosphonopeptides Suggest A Gated Peptide Binding Site”, Journal of Molecular Biology, 246(2): 344-355, 1995.
Mulot et al. “PHF-Tau From Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3 Beta”, FEBS Letters, 349(3): 359-364, 1994.
Mulot et al. “Phosphorylation of Tau by Glycogen Synthase Kinase-3 Beta In Vitro Produces Species With Similar Electrophoretic and Immunogenic Properties to PHF-Tau From Alzheimer's Disease Brain”, Biochemical Society Transactions, 23(1): 45S, 1995.
Myers et al. “IRS-1 Activates Phosphatidylinositol 3′-Kinase by Associating With SRC Homology 2 Domains of P85D”, Proc. Natl. Acad. Sci. USA, 89(21): 10350-10354, 1992.
Nikoulina et al. “Regulation of Glycogen Synthase Activity in Cultured Skeletal Muscle Cell From Subjects With Type II Diabetes: Role of Chronic Hyperinsulinemia and Hyperglycemia”, Diabetes, 46(6): 1017-1024, 1997.
Nikoulina et al. “Potential Role of Glycogen Synthase Kinase-3 in Skeletal Muscle Insulin Resitance of Type 2 Diabetes”, Diabetes, 49(2): 263-271, 2000.
Nonaka et al. “Chronic Lithium Treatment Robustly Protects Neurons in the Central Nervous Systems Against Excitotoxicity by Inhibiting N-Methyl-D-Aspartate Rectpro-Mediated Calcium Influx”, Proc. Natl. Acad. Sci. USA, 95: 2642-2647, 1998.
Otaka et al. “Synthesis and Application of N-Box-L-2-Amino-4-(Diethylphosphono)-4-,4-Difluorobutanoic Acid for Solid-Phase Synthesis of Nonhydrolyzable Phosphoserine Peptide Analogues”, Tetahedron Letters, 36(6): 927-930, 1995.
Othaka et al. “Development of New Methodology for the Synthesis of Functionalized α-Fluorophosphonates and Its Practical Application to the Preparation of Phosphopeptide Mimetics”, Chemical Communications, 12: 1081-1082, 2000.
Pap et al. “Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway”, The Journal of Biological Chemistry, 273: 19929-19932, 1998.
Phiel “Molecular Targets of Lithium Action”, Annual Review in Pharmacological Toxicology, 41: 789-831, 2001.
Roller et al. “Potent Inhibition of Protein-Tyrosine Phosphatase-IB Using the Phosphotyrosyl Mimetic Fluoro-O-Malonyl Tyrosine (FOMT)”, Bioorganics and Medicinal Chemistry Letters, 8(16): 2149-2150, 1998.
Rubinfeld et al. “Binding of GSK3Beta to the APC-Beta-Catenin Complex and Regulation of Complex Assembly”, Science, 272(5264): 1023-1026, 1996.
Schiller et al. “Synthesis for Side-Chain Cyclized Peptide Analogs on Solid Supports”, International Journal of Peptide Protein Research, 25: 171-177, 1985.
Shapiro et al. “Combained Fmoc-Alloc Strategy for a A General SPPS of Phosphoserine Peptides: Preparation of Phosphorylation-Dependent Tau Antisera”, Bioorganics and Medicinal Chemistry, 5(1): 147-156, 1997.
Sherman et al. “Compatibility of Thioamides With Reverse Turn Feat

Affiliated with

Also associated with

Rating

Glycogen synthase kinase-3 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycogen synthase kinase-3 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycogen synthase kinase-3 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2779731